This collaboration aims to advance innovations in drug delivery systems and the development of new therapeutic products.
The two companies will integrate ionizable lipids into CordenPharma’s complex LNP formulation services, closing a ‘critical gap’ in supporting biotech and pharmaceutical companies in developing, discovering, and manufacturing xRNA/xDNA therapies from early clinical phases to commercialization.
The partnership also complements CordenPharma’s recent initiatives, including peptide-decorated LNPs for targeted delivery and β-sitosterol for enhanced mRNA transfection.
Dr. Matthieu Giraud, CordenPharma’s senior director, global lipids and carbohydrates platform, commented: “Many therapeutic domains can benefit from the newly introduced LNP formulation that proved to be successful during the pandemic.
“At CordenPharma, we aim to consider independently each of the four pillars of an LNP formulation, namely the lipid functional excipients, to provide our customers with the most effective support in solving their therapeutic formulation challenges. This partnership augments our offer with a lean and attractive approach to LNP formulation that also reduces the growing IP challenges in the market.”
Under the terms of the agreement, Certest will provide access to its unique ionizable lipids platform, well supported by in vitro / in vivo and tox data.
CordenPharma will leverage its cGMP manufacturing capabilities, regulatory expertise, and market access to ensure high-quality GMP supply, supporting customers throughout their journey to market.
Nelson Fernandes, CEO of Certest, added: “The world of lipid nanoparticles is revolutionizing the pharmaceutical industry today. The results have been overwhelmingly positive, and advancements in the formulation of LNPs, along with the development of a robust library of ionizable lipids, are set to redefine the paradigm of the current situation.
“At Certest, we offer a powerful delivery platform, thanks to our ionizable lipids, that will enable clients to overcome nearly all therapeutic challenges. This collaboration is going to be a significant advancement for our clients.”
